Aarey Drugs Allots 11.5 Lakh Shares on Warrant Conversion, Capital Increases
Aarey Drugs & Pharmaceuticals Limited approved the allotment of 11,50,000 equity shares upon conversion of warrants. This brings the total converted warrants to 35,20,000 out of 50,00,000. The company's issued and paid-up capital increased to Rs. 31.87 crore.
The conversion of warrants and subsequent increase in paid-up capital can strengthen the company's financial structure. The amount involved is significant but does not represent a transformative event for a listed entity.
The company has successfully converted warrants into equity shares, increasing its capital base and reducing outstanding warrants, which is generally viewed positively.
Aarey Drugs & Pharmaceuticals Limited announced the outcome of its Board Meeting held on September 30, 2026. The meeting, which commenced at 11:30 AM and concluded at 12:30 PM, approved the allotment of 11,50,000 Equity Shares of face value Rs. 10 each. This allotment is pursuant to the conversion of Fully Convertible Equity Share Warrants, upon receipt of Rs. 47.85 per warrant (75% of the issue price of Rs. 63.80). The total amount aggregated to Rs. 5,50,27,500/-, with shares allotted to both promoter and non-promoter categories.
Following this allotment, the company's issued and paid-up capital has been revised. The total number of shares has increased from 30,724,303 to 31,874,303, with the total value of issued and paid-up capital now standing at Rs. 31,87,43,030/- (face value Rs. 10 each).
Previously, on August 6, 2026, the company had already converted 23,70,000 convertible warrants into equity shares. As of September 30, 2026, a total of 35,20,000 warrants have been converted into equity shares out of the initial 50,00,000 warrants. There are 14,80,000 convertible warrants still outstanding for conversion within the 18-month tenure from their allotment date of May 23, 2025.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.